Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...
Pharmaceutical Technology on MSN
Pfizer and Novavax ink $530m vaccine delivery licensing deal
Pfizer will now employ Novavax’s adjuvant, Matrix-M, into its vaccines across two disease areas.
Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season "With today's approval, we will work with our partner Sanofi to provide ...
StockStory.org on MSN
Why are Novavax (NVAX) shares soaring today
What Happened? Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the ...
Novavax’s president and CEO reviewed the company’s successes in 2025 and shared its growth strategy for 2026 and beyond at a ...
Novavax's vaccine targets the highly contagious omicron subvariant JN.1, which began circulating widely in the U.S. earlier this year. JN.1 only accounted for 0.2% of cases circulating nationwide as ...
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Novavax can ...
The vaccines subsector received a big fillip from Covid, but its potential extends far beyond combating pandemics. Dr Mike ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results